The Kentucky governor’s administration is refusing to release the names of medical marijuana dispensary license applicants, citing ‘preliminary’ status. This decision fuels concerns about out-of-state companies dominating the industry and lacks transparency, prompting a legal challenge and criticism from local farmers.
The New York Medical Cannabis Industry Association (NYMCIA) is suing the state, arguing a $20 million licensing fee for adult-use cannabis is unconstitutional, financially crippling, and designed to exclude existing medical operators from the recreational market. The lawsuit highlights the struggles faced by original medical marijuana providers and the potential impact on patient access.
Unity Rd., the first medical marijuana dispensary in South Dakota, is shutting its doors after facing numerous obstacles and a challenging legal environment. The closure comes on the heels of the state’s rejection of recreational cannabis legalization and highlights the ongoing struggles of the cannabis industry in the state.
Six years after legalizing medical marijuana, families in the UK are demanding change as the NHS continues to fall short in providing access to life-saving cannabis-based medications. Parents of children suffering from treatment-resistant epilepsy are particularly vocal, citing the effectiveness of medical marijuana compared to conventional treatments. Despite legal access, only a handful of patients have received NHS prescriptions, leaving many families struggling to afford private options.
Tilray Medical, a division of Tilray Brands, Inc., has announced positive results from a clinical trial showing that oral cannabis extract significantly reduces chemotherapy-induced vomiting (CINV) in adults. The study also highlighted the launch of a new podcast series, ‘Men’s Health on Tap,’ focusing on breaking down stigmas surrounding men’s health concerns.
Canadian medical marijuana giant Aurora Cannabis Inc. reported strong second-quarter financial results, with revenue reaching CA$81.1 million, driven by robust growth in its global medical cannabis business. The company’s international revenue surged 93%, exceeding Canadian medical revenue for the first time, highlighting its strategic focus on expanding into lucrative international markets. Aurora’s Q2 2025 performance also saw a significant increase in adjusted EBITDA and a positive outlook for the coming quarters.
This article explores the evolving landscape of cannabis regulations around the world, highlighting significant changes in Poland, Thailand, Japan, and Australia. From stricter access to medical marijuana in Poland to ultra-strict THC limits in Japan, the article examines the various approaches countries are taking towards cannabis use.
A new study reveals that 90% of illegal cannabis samples in the UK contain harmful contaminants, including mold, yeast, lead, and bacteria. The research, conducted by Curaleaf Clinic in partnership with Manchester Metropolitan University, highlights the dangers of unregulated cannabis and calls for increased awareness, accessibility to medical cannabis, and policy changes.
Curaleaf International, a subsidiary of US cannabis giant Curaleaf Holdings, is calling on the British government to take immediate action against the rapidly expanding online illicit cannabis market. The company’s report highlights the dangers of unregulated cannabis, including contamination with harmful substances, and advocates for increased access to legal, regulated medical cannabis.
France’s medical marijuana trial, set to end in March 2024, faces an uncertain future. While an amendment aims to extend the trial until December 2025, political issues and delays could hinder its implementation. This leaves thousands of patients in limbo, with the outcome depending on the government’s decision in the coming weeks.
